Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-01 rilvegostomig in advanced or metastatic non-small cell lung cancer
NL-OMON54261Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rilvegostomig in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability and Discontinuation due to toxicity. Started Dec 2021; status: recruiting.
02
Drugs
rilvegostomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON54261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54261.